search button

Effect of liver toxicity on clinical outcome of patients with non‑small‑cell lung cancer treated with pemetrexed

  • Authors:
    • Yuichi Sakamori
    • Young Hak Kim
    • Hironori Yoshida
    • Takashi Nakaoku
    • Hiroki Nagai
    • Yoshitaka Yagi
    • Hiroaki Ozasa
    • Michiaki Mishima

  • View Affiliations

  • Published online on: November 4, 2014     https://doi.org/10.3892/mco.2014.452
  • Pages: 334-340
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Liver toxicity (LT) is a common side effect of pemetrexed (PEM); however, the effect of LT on clinical outcome has not been investigated in patients with non‑small‑cell lung cancer (NSCLC) treated with PEM. Between June, 2009 and June, 2012, a total of 95 chemo‑naive NSCLC patients received a PEM‑containing regimen in our hospital. We reviewed the medical records of those 95 patients and evaluated the incidence of LT. Furthermore, we investigated the association between LT and clinical outcome. In this analysis, LT was defined as any grade of aspartate aminotransferase or alanine aminotransferase elevation. A total of 67 patients (70.5%) developed LT, which occurred mostly during the first treatment cycle. Among these, 10 patients (10.5%) required a delay in treatment or a dose reduction from the subsequent cycle and PEM discontinuation was required in 1 patient. The response rate (RR) was 43.3 and 21.4% in patients with and in those without LT, respectively (P=0.0387). The median progression‑free survival (PFS) and overall survival (OS) were 6.3 and 24.2 months in patients with LT and 2.9 and 18.3 months in patients without LT, respectively (P<0.0001 for PFS and P=0.2426 for OS). The multivariate analysis demonstrated that LT exerted a significant positive effect on PFS (hazard ratio = 0.341; P<0.0001). In conclusion, LT was frequently observed in NSCLC patients treated with PEM; however, it was generally easily manageable. The improvement in RR and PFS observed in patients with LT suggested that LT may be a useful predictor of a favorable outcome in this patient population.
View Figures
View References

Related Articles

Journal Cover

March-2015
Volume 3 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.4
  • Ranked
    (total number of cites)
  • CiteScore: 2.8
  • CiteScore Rank: Q3: #250/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.55
  • SCImago Journal Rank (SJR): 0.446
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Sakamori Y, Kim YH, Yoshida H, Nakaoku T, Nagai H, Yagi Y, Ozasa H and Mishima M: Effect of liver toxicity on clinical outcome of patients with non‑small‑cell lung cancer treated with pemetrexed. Mol Clin Oncol 3: 334-340, 2015.
APA
Sakamori, Y., Kim, Y.H., Yoshida, H., Nakaoku, T., Nagai, H., Yagi, Y. ... Mishima, M. (2015). Effect of liver toxicity on clinical outcome of patients with non‑small‑cell lung cancer treated with pemetrexed. Molecular and Clinical Oncology, 3, 334-340. https://doi.org/10.3892/mco.2014.452
MLA
Sakamori, Y., Kim, Y. H., Yoshida, H., Nakaoku, T., Nagai, H., Yagi, Y., Ozasa, H., Mishima, M."Effect of liver toxicity on clinical outcome of patients with non‑small‑cell lung cancer treated with pemetrexed". Molecular and Clinical Oncology 3.2 (2015): 334-340.
Chicago
Sakamori, Y., Kim, Y. H., Yoshida, H., Nakaoku, T., Nagai, H., Yagi, Y., Ozasa, H., Mishima, M."Effect of liver toxicity on clinical outcome of patients with non‑small‑cell lung cancer treated with pemetrexed". Molecular and Clinical Oncology 3, no. 2 (2015): 334-340. https://doi.org/10.3892/mco.2014.452